SecBot SecBot
8-K ·Filed Jul 1, 2026

CRMD

CorMedix Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001410098-26-000037
8-K material event: Items 4.01
Actionable Insight • Neutral

Monitor the next 10-Q filing for updates on remediation of the material weakness and any further auditor-related disclosures. The appointment of EY may improve audit credibility, but the pattern of auditor changes warrants close attention to financial reporting quality.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.47
T+0 close · Jul 1, 2026 · via day close
Latest settled
−8.26%
T+60 · $7.77
Vs SPY
−11.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 1 $8.47entry
  2. T+1 · 5mo ago +3.31%α +3.44% · $8.75
  3. T+5 · 4mo ago +4.72%α +4.46% · $8.87
  4. T+20 · 4mo ago −15.11%α −12.93% · $7.19
  5. T+60 · 8w ago −8.26%α −11.22% · $7.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CorMedix Inc. dismissed its independent auditor CBIZ CPAs P.C. and appointed Ernst & Young LLP (EY) as its new independent registered public accounting firm for FY2026. The change was approved by the Audit Committee on June 25, 2026, with no disagreements between the company and CBIZ, though a previously disclosed material weakness in internal controls over financial reporting was noted as a reportable event. The move from a mid-tier firm to a Big 4 auditor may signal a step up in audit quality, but the second auditor change in just over a year and the existing material weakness warrant caution.

Key Facts

  • CorMedix dismissed CBIZ CPAs P.C. as its independent auditor on June 25, 2026.
  • Appointed Ernst & Young LLP (EY) as the new independent auditor for the fiscal year ending December 31, 2026.
  • No disagreements (as defined in Item 304(a)(1)(iv)) occurred with CBIZ from April 17, 2025 through June 25, 2026.
  • A material weakness in internal control over financial reporting was disclosed as a reportable event, previously reported in the FY2025 10-K.
  • CBIZ agreed with the statements in the 8-K via Exhibit 16.1 letter dated July 1, 2026.

Financial Impact

No financial figures provided; the change in auditor does not directly impact reported financials.

internal controls

Risk Factors

  • Continued material weakness in internal controls could lead to restatements or delayed filings.
  • Further auditor changes may signal underlying accounting or governance issues.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001410098-26-000037
Exhibit: exhibit161letterfromcbiz.htm0001410098-26-000037
Document: 0001410098-26-000037-index-headers.html0001410098-26-000037
Document: 0001410098-26-000037-index.html0001410098-26-000037
Document: 0001410098-26-000037.txt0001410098-26-000037

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 1, 2026